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OBJECTIVEdWe tested genetic associations with weight loss and weight regain in the Di-
abetes Prevention Program, a randomized controlled trial of weight loss–inducing interventions
(lifestyle and metformin) versus placebo.
RESEARCHDESIGNANDMETHODSdSixteenobesity-predisposingsinglenucleotide
polymorphisms (SNPs) were tested for association with short-term (baseline to 6 months) and
long-term (baseline to 2 years) weight loss and weight regain (6 months to study end).
RESULTSdIrrespectiveoftreatment,theAla12alleleatPPARGassociatedwithshort-andlong-term
weight loss (20.63 and 20.93 kg/allele, P # 0.005, respectively). Gene–treatment interactions were
observedfor short-term(LYPLAL1rs2605100,Plifestyle*SNP=0.032;GNPDA2rs10938397,Plifestyle*SNP=
0.016; MTCH2 rs10838738, Plifestyle*SNP = 0.022) and long-term (NEGR1 rs2815752, Pmetformin*SNP =
0.028;FTO rs9939609,Plifestyle*SNP =0 . 0 4 4 )we i gh tl o s s .T h re eo f1 6S N P swe r ea s s o c i a t e dw i t hwe i gh t
regain (NEGR1 rs2815752, BDNF rs6265, PPARG rs1801282), irrespective of treatment. TMEM18
rs6548238 and KTCD15 rs29941 showed treatment-speciﬁc effects (Plifestyle*SNP , 0.05).
CONCLUSIONSdGenetic information may help identify people who require additional
support to maintain reduced weight after clinical intervention.
Diabetes Care 35:363–366, 2012
M
ultiple obesity-predisposing gene
variants are known (1,2), which
mayinteractwithlifestyletomod-
ifyobesityrisk(3).Itisunknownwhether
these variants inﬂuence weight regain
(WR) after intentional weight loss (WL).
We therefore tested associations of 16
obesity-predisposing variants with weight
change in Diabetes Prevention Program
(DPP) participants.
RESEARCH DESIGN AND
METHODSdThe DPP is described
elsewhere (4,5). In brief, 3,234 over-
weight/obese adults with impaired glu-
cose tolerance were randomly assigned
to placebo, 850 mg metformin twice
daily, or intensive lifestyle modiﬁcation
aimed at ;150 min of physical activity
per week and ;7% WL, to compare ef-
fects on diabetes incidence. Participants
provided written informed consent, and
institutional review boards of 27 DPP
study centers approved the study.
Participants
Of 3,597 participants with baseline and
1-yeardataavailable,93.3%consentedto
geneticanalyses.Ofthese, 56.1%werenon-
Hispanicwhite(NHW),20.4%wereAfrican
American,16.7%wereHispanic,4.4%were
Asian American, and 2.5% were American
Indian; on average participants were
middle-aged and obese (see Supplemen-
tary Table 1 for participant characteristics).
Genotyping
Sixteen obesity-predisposing variants re-
ported elsewhere (1,2) or in the DPP (6)
were genotyped as described previously
(6); genotyping success rates exceeded
99% (Supplementary Table 2).
Statistical analysis
Analyses were performed using SAS v9.2
(Cary, NC). Predictor variables were single
nucleotide polymorphisms (SNPs), with
effectallelescodedconsistentwiththeas-
sociation of each SNP with BMI or waist
circumference in published meta-analyses
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Pathophysiology/Complications
BRIEF REPORT(SupplementaryTable3)(2).Geneticrisk
scores were constructed by summing ef-
fect alleles (see Supplementary Data) (7).
Models are annotated in Supplementary
Data.
Primary end points are 1) short-term
WL (baseline to 6 months), 2) long-term
WL (baseline to 2 years), and 3) average
rate of WR (6 months to study end (range
2–4.5 years). WL analyses included all
participants, whereas WR analyses in-
cluded1,411participantswhohadachieved
$3% WL at 6 months. Analyses were
conducted in the pooled sample adjusting
for self-reported ethnicity; sensitivity an-
alyses were repeated in NHW only to
rule out population stratiﬁcation. Unless
there was statistical evidence of gene x
treatment interactions, data were pooled
from the three study arms and models
were adjusted for age, sex, ethnicity, treat-
ment, and baseline value for the depen-
dent variable. Where such interactions
were observed, treatment-speciﬁc genetic
effects were estimated. For general linear
models assuming additive allele effects
(except Pro12Ala, which was coded
with Pro12Pro vs. Ala123), nominal
two-sided P values are reported. All P val-
ues for the same outcome are adjusted for
multiple comparisons, and signiﬁcant SNP
effects are reported (8): for short-term WL,
there are three signiﬁcant SNP*treatment
interactions (13 + (3*3) = 22 tests are cor-
rectedfor);forlong-termWL,therearetwo
signiﬁcant interactions (14 + (3*2) = 20
tests are corrected for); and for WR, there
aresixsigniﬁcantinteractions(10+(6*3)=
28 tests are adjusted for).
RESULTSdBaseline data are reported
inSupplementaryTables1and4.Pvalues
Table 1dSummary of association data for each of 16 known obesity loci and short-term (6 months) change in weight (kilograms
per year), long-term (2 years) change in weight (kilograms per year), and rate of WR from 6 months through trial end (kilograms
per year) in the overall DPP cohort and each treatment arm if signiﬁcant SNP treatment interactions were detected
Nearest gene SNP
Effect (other)
allele
6-Month WL (kg/allele;
n = 3,085)
2-Year WL (kg/allele;
n =3 , 0 1 5 )
WR (kg/year/allele;
n =1 , 4 1 1 )
Coefﬁcient
(SE) P value
Coefﬁcient
(SE) P value
Coefﬁcient
(SE) P value
MC4R rs17782313 C(T) 0.11 (0.14) 0.433 20.10 (0.20) 0.633 20.22 (0.18) 0.241
FTO rs9939609 A(T) 20.12 (0.12) 0.336 0.20 (0.16) 0.207
MTCH2 rs10838738 G(A) 0.02 (0.19) 0.899 20.10 (0.18) 0.580
NEGR1 rs2815752 A(G) 20.20 (0.13) 0.130 20.35 (0.16) 0.034
TMEM18 rs6548238 C(T) 0.11 (0.17) 0.519 0.20 (0.24) 0.408
SH2B1 rs7498665 T(C) 0.01 (0.13) 0.928 20.01 (0.18) 0.934 0.06 (0.17) 0.729
SEC16B rs10913469 C(T) 0.01 (0.15) 0.938 0.08 (0.21) 0.710 0.20 (0.20) 0.330
BDNF rs6265 C(T) 20.04 (0.17) 0.828 0.35 (0.24) 0.140 0.55 (0.21) 0.011
FAIM2 rs7138803 A(G) 0.07 (0.13) 0.625 20.07 (0.19) 0.692 0.12 (0.18) 0.504
KTCD15 rs29941 G(A) 20.06 (0.14) 0.639 20.16 (0.19) 0.404
PPARG rs1801282 Ala(Pro) 20.63 (0.22) 0.005 20.93 (0.31) 0.003 20.79 (0.27) 0.004
LYPLAL1 rs2605100 G(A) 0.22 (0.20) 0.272 20.16 (0.18) 0.399
ETV5 rs7647305 C(T) 0.05 (0.14) 0.726 20.08 (0.20) 0.675 0.17 (0.18) 0.360
GNPDA2 rs10938397 G(A) 0.08 (0.18) 0.668 0.09 (0.16) 0.577
TFAP2B rs987237 G(A) 20.05 (0.15) 0.725 0.15 (0.21) 0.483 0.12 (0.20) 0.530
MSRA rs7826222 G(C) 20.05 (0.16) 0.751 20.09 (0.23) 0.691 20.14 (0.21) 0.508
Treatment-speciﬁc SNP effects Lifestyle Metformin Placebo
6-Month WL (kg/allele; for lifestyle,
n = 1,041; for metformin, n = 1,024;
for placebo, n = 1,020)
MTCH2 rs10838738 G(A) 20.12 (0.28) 0.666 20.02 (0.21) 0.932 0.37 (0.21) 0.079
LYPLAL1 rs2605100 G(A) 0.35 (0.29) 0.234 0.19 (0.22) 0.389 20.11 (0.22) 0.600
GNPDA2 rs10938397 G(A) 0.11 (0.26) 0.676 0.12 (0.19) 0.544 0.40 (0.19) 0.038
2-Year WL (kg/allele; for lifestyle,
n = 999; for metformin, n = 1,004;
for placebo, n = 1,012)
FTO rs9939609 A(T) 0.56 (0.36) 0.124 20.41 (0.27) 0.134 20.29 (0.26) 0.269
NEGR1 rs2815752 A(G) 20.35 (0.37) 0.346 20.79 (0.29) 0.006 0.19 (0.28) 0.496
WR rate (kg/year/allele; for lifestyle,
n = 808; for metformin, n = 409;
for placebo, n = 194)
TMEM18 rs6548238 C(T) 0.62 (0.31) 0.044 0.13 (0.40) 0.745 20.78 (0.55) 0.158
KTCD15 rs29941 G(A) 0.50 (0.24) 0.041 20.17 (0.31) 0.592 20.36 (0.39) 0.364
Baseline age, sex, and ethnicity are adjusted for in all analyses. Allele effects are in the pooled sample of three treatment groups. The empty cells correspond to cases
with signiﬁcant treatment and allele interactions, and treatment-speciﬁc allele effects are estimated. Listed P values are not adjusted for multiple comparisons.
Treatment-speciﬁc allele effects are reported here when allele effects differ in the three treatment groups.
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Genetics of weight regaininTable1areobtainedfromtheregressions;
however,onlySNPsthatremainstatistically
signiﬁcant after adjusting for multiple com-
parisons are reported in this section.
WL
Short- and long-term WL were greatest in
the lifestyle intervention group, and both
lifestyle and metformin groups had sig-
niﬁcantly greater WL than the placebo
(control) group (4,5). Irrespective of treat-
ment, the minor Ala12 allele at PPARG
was associated with short- and long-term
WL (Table 1). Statistically signiﬁcant gene-
lifestyle interactions were observed for
short-term(LYPLAL1 rs2605100; GNPDA2
rs10938397; MTCH2 rs10838738) and
long-term (NEGR1 rs2815752; FTO
rs9939609) WL (Pinteraction, 0.05).
WR
The rate of WR (in kilograms per year)
from 6 months to study end was greatest
in the lifestyle group and least in the
placebo group (Supplementary Table 1).
Those who lost $3% body weight from
baseline to 6 months had a mean (SD)
WR of 0.94 (64.68) kg/year. Three of
16 SNPs were associated with WR
(NEGR1 rs2815752, BDNF rs6265,
PPARG rs1801282), irrespective of treat-
ment. TMEM18 rs6548238 and KTCD15
rs29941 showed treatment-speciﬁce f -
fects. In aggregate, the risk alleles associ-
ated with WR associated with faster WR
(0.274 kg/year/allele [SE = 0.097]; P =
0.005), whereas these alleles had no de-
tectable impact on WR in the control
group (Supplementary Fig. 1).
Sensitivity analyses performed in
NHW participants, who are essentially
free of admixture (9), yielded effect esti-
mates of comparable magnitude, indicat-
ing that population stratiﬁcation does not
confound our ﬁndings (Supplementary
Table 5).
Mediator analyses
Analyses were also performed assessing
putative mediating roles of speciﬁc life-
style factors (details in Supplementary
Data). However, none explained a statis-
tically signiﬁcant amount of variance in
the SNP-phenotype relationships.
CONCLUSIONSdThis is, to our
knowledge, the ﬁrst report of effects of
validated obesity-predisposing genotypes
on long-term WR after successful inten-
tional WL. We found that three SNPs
(NEGR1rs2815752,BDNFrs6265,PPARG
rs1801282) predicted WR, irrespective of
type of WL therapy, two of which (BDNF
rs6265, PPARG Pro12Ala) were robust to
correction for multiple hypothesis testing.
Two other variants (TMEM18 rs6548238,
KTCD15 rs29941) interacted with treat-
ment modality to inﬂuence WR. We also
replicated several associations reported
previously with baseline obesity metrics
(Supplementary Table 4).
Our WR ﬁndings are perhaps most
clinically relevant, since these might help
target susceptible individuals and thus
improve long-term effects of WL inter-
ventions. One of few published genetic
association studies on WR found that the
minor allele at the Pro12Ala locus asso-
ciated with greater regain 1 year after a
6-month hypocaloric diet intervention
ended, also noting reductions in the rate
of fat oxidation in Ala12 allele carriers but
not in Pro12 homozygotes (10), ﬁndings
supporting those reported here. A second
small study (11) found a similar association
between the Pro12Ala genotype and WR,
whereas a third small study (12) reported
no effect.
Despite plausible mechanisms by
which the genetic effects reported here
are expressed, we were unable to detect
statisticallysigniﬁcantmediators.Although
the genetic variants we studied may act
independently of the selected mediators, it
is also possible some of our ﬁndings are
false-negative, owing to the relatively small
sampleandindirectmeasures.Ourstudyis
also limited by the absence of information
on lifestyle behaviors after 12 months of
intervention, which may have hampered
thedetectionofmediators.Finally,thehy-
perglycemicnatureoftheDPPcohortmay
limit generalizability of our ﬁndings.
In summary, our ﬁndings offer novel
insights into the mechanisms inﬂuencing
the propensity for WR after intentional
WL. This information may help target
individuals who require additional sup-
port to maintain reduced weight in inter-
vention settings.
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